There is no verified public evidence that Cliff Asness and Vas Narasimhan have a direct personal, family, executive, or business partnership. The strongest documented links between them are institutional: both have significant ties to the University of Chicago, while investment products managed by Asness’s AQR Capital Management have held shares of Novartis, the pharmaceutical company led by Narasimhan.
A review of their official biographies, board memberships, university records, corporate disclosures, and investment filings does not show them serving together at the same company or organization as of September 2026. Their careers instead represent two different fields: Asness in quantitative investing and Narasimhan in medicine, biotechnology, and pharmaceutical leadership.
Are Cliff Asness and Vas Narasimhan Directly Connected?
No documented direct relationship between cliff asness and vas narasimhan appears in authoritative public records reviewed for this article. They are not known to be relatives, business partners, co-founders, colleagues, or members of the same corporate board.
There are, however, several genuine points of institutional overlap that may explain why their names appear together in searches.
| Area | Cliff Asness | Vas Narasimhan | Verified overlap? |
|---|---|---|---|
| Main profession | Quantitative investing | Pharmaceuticals and medicine | No |
| Main organization | AQR Capital Management | Novartis | No |
| University of Chicago | MBA and PhD alumnus, major donor | Bachelor’s alumnus and university trustee | Yes |
| Novartis investment exposure | AQR-managed investment funds have held Novartis shares | CEO of Novartis | Indirect |
| Biomedical organizations | Broad Institute board member | Pharmaceutical executive, physician-scientist | Related field, different roles |
| Shared corporate board | None identified | None identified | No |
| Family relationship | None documented | None documented | No |
The distinction matters. An investment manager holding shares in a company does not establish a personal relationship between the investment firm’s founder and the company’s CEO.
Who Is Cliff Asness?
Clifford S. Asness is the founder, managing principal, and chief investment officer of AQR Capital Management, a quantitative investment firm established in 1998 by Asness, David Kabiller, Robert Krail, and John Liew. AQR uses systematic research involving economics, behavioral finance, market data, and quantitative methods across equity, macro, arbitrage, and multi-strategy investments.
Before starting AQR, Asness worked at Goldman Sachs, where he became managing director and director of quantitative research for its asset-management division. His academic work and subsequent investment career have focused heavily on areas such as value investing, momentum, diversification, factor investing, and quantitative portfolio construction.
Asness has also published research in journals including The Journal of Finance, The Journal of Financial Economics, Financial Analysts Journal, and The Journal of Portfolio Management. His work has received multiple investment-research awards, including five Bernstein Fabozzi/Jacobs Levy Awards and recognition from the CFA Institute.
Asness and the University of Chicago
The University of Chicago is one of the clearest links between Asness and Narasimhan.
Asness received an MBA with high honors and a PhD in finance from the University of Chicago. He studied under influential economist Eugene Fama and served as Fama’s teaching assistant.
His involvement with the university continued well beyond graduation. In 2018, Asness and AQR co-founder John Liew contributed $10 million to support junior faculty fellowships at Chicago Booth.
In October 2024, Asness and Liew made another $60 million gift supporting Booth’s Master in Finance program. The university subsequently named it the Asness and Liew Master in Finance Program.
Asness’s Links to Scientific Research
Asness’s professional career is primarily financial, but his board activities extend beyond investing.
He serves on the board of directors of the Broad Institute of MIT and Harvard, a major biomedical and genomic research institution. The Broad Institute’s current board listing identifies Asness alongside leaders from Harvard, MIT, Dana-Farber Cancer Institute, investment firms, and other institutions.
His official AQR biography also lists board roles with the American Enterprise Institute and Commentary magazine.
That biomedical connection is noteworthy in comparison with Narasimhan’s career, but it still does not demonstrate that Asness and Narasimhan personally work together.
Who Is Vas Narasimhan?
Vasant “Vas” Narasimhan is an American physician-scientist and the chief executive officer of Novartis, one of the world’s major pharmaceutical companies.
Narasimhan joined Novartis in 2005 and subsequently held leadership positions including Global Head of Development for Novartis Vaccines, Global Head of Development for Novartis Pharmaceuticals, and Global Head of Drug Development and Chief Medical Officer. He became CEO on February 1, 2018.
His educational background is heavily oriented toward science, medicine, and public policy. Narasimhan earned a bachelor’s degree in biological sciences from the University of Chicago, followed by an MD from Harvard Medical School and a master’s degree in public policy from Harvard’s Kennedy School.
Novartis says Narasimhan has overseen the approval of more than 35 novel medicines and vaccines during his career. His leadership has increasingly concentrated the company around innovative medicines and platforms such as radioligand therapies, siRNA medicines, and cell and gene therapies.
Also Read: Jessica Chastain and Vas Narasimhan
Vas Narasimhan’s University of Chicago Connection
Narasimhan received his undergraduate degree from the University of Chicago in 1998.
His relationship with the university later expanded into governance. In 2023, the University of Chicago announced that Narasimhan had been elected to its Board of Trustees, together with Paul Carbone, Richard Gonzalez, and Hilary Krane.
This produces a genuine institutional connection with Asness. Both are University of Chicago alumni, although they attended different schools and at different times. Asness studied finance at Chicago Booth, while Narasimhan studied biological sciences as an undergraduate.
Asness subsequently became a major Booth donor, while Narasimhan became a university trustee. There is still no evidence in the university records reviewed here that this institutional connection represents a personal partnership between them.
The AQR and Novartis Investment Connection
A second meaningful link exists through the capital markets.
AQR is an investment manager, and its systematic strategies can include shares of large international companies such as Novartis. An SEC-filed AQR shareholder report covering investments as of March 31, 2026 listed Novartis AG registered shares at 2.4% of net assets in an AQR international portfolio, making Novartis one of the portfolio’s largest reported holdings at that date.
AQR’s International Multi-Style strategy systematically evaluates non-US companies using characteristics including value, momentum, and quality. Its official materials describe a quantitative investment process rather than a strategy built around personal relationships with corporate executives.
This distinction is essential. An AQR-managed fund owning Novartis securities does not mean that Cliff Asness personally selected the shares, personally owns the reported position, advises Vas Narasimhan, or has a special relationship with Novartis management.
Large investment firms frequently hold hundreds or thousands of securities through funds, separately managed accounts, and other strategies. Portfolio positions also change over time.
How AQR Fits Into Cliff Asness’s Career
AQR was founded in 1998 and built much of its identity around academically influenced quantitative investing. The letters AQR originally reflect “Applied Quantitative Research,” which captures the firm’s emphasis on systematic analysis rather than traditional discretionary stock picking.
Regulatory disclosures stated that AQR had approximately $187.3 billion in assets under management as of December 31, 2025. That figure represents money managed by the firm, not Asness’s personal wealth.
Asness remains one of the investment professionals associated with a number of AQR strategies, and the firm’s current leadership page continues to identify him as managing and founding principal.
How Novartis Has Changed Under Vas Narasimhan
Narasimhan has overseen a substantial reshaping of Novartis since becoming CEO in 2018.
The company has moved toward a more concentrated innovative-medicines model, while increasing its focus on areas such as oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic diseases. Novartis’s major products include Entresto, Cosentyx, Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio.
For full-year 2025, Novartis reported $54.532 billion in net sales, up 8% from 2024 in both reported dollars and constant currencies. Operating income reached $17.644 billion, while reported net income was $13.967 billion.
The company’s latest reported quarterly results before this article was prepared were for the second quarter of 2026. Novartis recorded $14.408 billion in Q2 net sales, up 3% in reported dollars and 1% in constant currencies, while reaffirming its full-year guidance.
These results provide context for why a quantitative international-equity manager such as AQR might encounter Novartis in its investment universe, but they should not be interpreted as evidence of personal collaboration between Asness and Narasimhan.
Narasimhan’s Expanding Role in Artificial Intelligence
Narasimhan’s responsibilities expanded beyond Novartis in April 2026 when Anthropic’s Long-Term Benefit Trust appointed him to Anthropic’s board of directors.
Anthropic described his experience bringing medicines through highly regulated development and approval processes as particularly relevant to governing advanced technology safely and at scale.
Anthropic’s current governance page lists Narasimhan among its directors alongside Dario Amodei, Daniela Amodei, Yasmin Razavi, Reed Hastings, and Chris Liddell.
The appointment is particularly relevant as artificial intelligence becomes increasingly important in biological research and pharmaceutical development. It does not create a known connection with Asness, however.
Where Their Careers Clearly Differ
Although both men operate at the highest levels of large institutions, their professional responsibilities are fundamentally different.
Asness studies markets, risk, expected returns, diversification, and systematic investment strategies. His career combines academic finance with professional asset management.
Narasimhan is responsible for running a multinational medicines company. His work involves pharmaceutical research, clinical development, regulatory approvals, drug commercialization, healthcare access, and corporate strategy.
Their public board networks are also distinct. Asness serves on the Broad Institute board and other organizations, while Narasimhan’s current mandates include Anthropic, PhRMA-related responsibilities, the University of Chicago, Harvard Medical School affiliations, and African Parks.
What Can Actually Be Said About Cliff Asness and Vas Narasimhan?
The evidence supports three careful conclusions.
First, there is no publicly established direct relationship between the two men in the authoritative corporate, academic, and organizational sources reviewed.
Second, they have an important shared University of Chicago connection. Asness is a Booth alumnus and significant university donor, while Narasimhan is an undergraduate alumnus and University trustee.
Third, an indirect financial-market connection exists because AQR-managed investment portfolios have held Novartis shares. That is an institutional investment relationship between a money manager and a publicly traded company, not evidence of a personal relationship between Asness and Narasimhan.
FAQ
Are Cliff Asness and Vas Narasimhan business partners?
No verified source reviewed shows Cliff Asness and Vas Narasimhan as business partners. Asness leads AQR Capital Management, while Narasimhan leads Novartis.
Do Cliff Asness and Vas Narasimhan know each other personally?
There is no authoritative public information establishing a personal friendship or other private relationship between them. They belong to some overlapping institutional circles, particularly around the University of Chicago, but that alone does not establish a personal connection.
What is the University of Chicago connection between Cliff Asness and Vas Narasimhan?
Asness earned his MBA and PhD from the University of Chicago Booth School of Business. Narasimhan earned his bachelor’s degree from the University of Chicago and was elected to the University’s Board of Trustees in 2023.
Does Cliff Asness’s AQR invest in Novartis?
AQR-managed investment products have reported Novartis holdings. An SEC-filed AQR fund report showed Novartis at 2.4% of the relevant portfolio’s net assets as of March 31, 2026.
That position should not be interpreted as Asness’s personal investment or evidence of a relationship with Narasimhan.
What does Cliff Asness do today?
Asness remains founder, managing principal, and chief investment officer of AQR Capital Management. He is also active in investment research and serves on boards including the Broad Institute.
What does Vas Narasimhan do today?
Narasimhan remains CEO of Novartis, a role he has held since 2018. In 2026, he also joined Anthropic’s board while continuing other institutional and nonprofit responsibilities.
Also Read: Martin Scorsese and Vas Narasimhan
